How the Mediterranean Diet’s Gut Bacteria May Explain Its Heart Benefits

If you've been told to eat more like people in Greece or southern Italy to protect your heart, there's a specific biological reason that advice might work, and it lives in your gut. A new review in Current Atherosclerosis Reports pulls together evidence from major randomized trials to make the case that the Mediterranean diet's cardiovascular benefits are not just about swapping butter for olive oil, they are partly routed through changes in the trillions of bacteria living in your intestines. For anyone whose blood pressure, cholesterol, or family history has them worried about heart disease, that link matters: it suggests gut health and cardiovascular health are more entangled than a simple "eat better" recommendation implies.

Key takeaways:

• A new review argues the gut microbiome may partly explain, not just accompany, the Mediterranean diet's cardiovascular benefits.
• In one trial (DIRECT-PLUS), microbiome changes statistically accounted for an estimated 10 to 20% of a Green Mediterranean diet's effect on weight, waist size, and calculated heart-disease risk, though this figure is unreplicated.
• The Mediterranean diet itself already has strong trial evidence for lowering heart attack and stroke risk: the CORDIOPREV trial found a 27% reduction in major cardiovascular events over 7 years in people with existing heart disease.
• The gut microbiome is not yet a usable clinical target; microbiome tests or probiotics are not proven to add cardiovascular benefit on top of the diet itself.

Gut Microbiome Changes May Partly Explain Mediterranean Diet's Heart Protection

A review of Mediterranean diet research finds that shifts in gut bacteria (the microbiome, the community of trillions of microorganisms living mainly in the large intestine) may partly explain why the diet lowers cardiovascular risk, rather than the diet acting directly on the heart and blood vessels alone. The review, led by Adrián Hernández-Cacho and colleagues, synthesizes evidence from randomized controlled trials and cohort studies showing that people who closely follow a Mediterranean diet, rich in vegetables, legumes, whole grains, fish, nuts, and extra-virgin olive oil, develop a gut microbiome enriched with fiber-degrading bacteria and short-chain fatty acid (SCFA, a metabolic byproduct that feeds gut cells and reduces inflammation) producers. Among the specific microbes flagged across multiple trials are Faecalibacterium prausnitzii, Roseburia, and members of the Lachnospiraceae and Ruminococcaceae bacterial families, all known for fermenting dietary fiber into SCFAs like butyrate. In the most direct evidence for a causal role, a mediation analysis of the DIRECT-PLUS trial found that microbiome changes accounted for an estimated 10 to 20% of a Green Mediterranean diet's effects on weight, waist circumference, and a calculated 10-year cardiovascular risk score (the Framingham risk score).

People With Heart Disease Risk or Metabolic Syndrome Stand to Benefit Most

The findings are most relevant to people who already have elevated cardiovascular risk factors, established heart disease, obesity, or metabolic syndrome (a cluster of conditions including high blood pressure, high blood sugar, and abnormal cholesterol that raises heart disease and diabetes risk), because those are the groups the underlying trials actually studied. In the CORDIOPREV trial, patients with established coronary heart disease who adopted a Mediterranean diet had a 27% reduction in the risk of major cardiovascular events, including stroke, heart attack, and cardiovascular death, compared with those on a low-fat diet, over 7 years of follow-up. The PREDIMED trial, a landmark primary-prevention study, found that people at high cardiovascular risk who followed a Mediterranean diet supplemented with extra-virgin olive oil or nuts had a lower incidence of major cardiovascular events (stroke, heart attack, and cardiovascular death) than those assigned to a low-fat control diet. For someone managing insulin resistance, high triglycerides, or a family history of heart attack or stroke, this review argues the gut may be one of the biological pathways worth understanding, not just a side effect of eating well.

Randomized Trials Like PREDIMED and CORDIOPREV Anchor the Evidence

The review draws its confidence primarily from randomized controlled trials, the study design where participants are randomly assigned to different diets so researchers can more confidently attribute outcomes to the diet itself rather than other lifestyle differences. Intervention lengths across the microbiome-focused trials ranged from 8 weeks to 12 months, with sample sizes as small as 29 participants (a crossover trial by Vitale and colleagues) and as large as 400 (the PREDIMED-Plus microbiome substudy, in older adults with obesity and metabolic syndrome). Most studies profiled the microbiome using 16S rRNA gene sequencing (a technique that identifies bacterial types by reading a single conserved gene), though a growing number now use shotgun metagenomics, which sequences all the genetic material in a stool sample and can detect functional pathways, not just which bacteria are present. This is a review article, meaning it synthesizes and interprets findings from dozens of existing studies rather than reporting new experimental data of its own.

What This Means If You're Managing Cardiovascular Risk

For a reader trying to translate this into something actionable, the honest answer is that adopting a Mediterranean-style eating pattern (more legumes, vegetables, whole grains, olive oil, nuts, and fish; less red and processed meat) is already supported by strong cardiovascular outcome data from trials like PREDIMED and CORDIOPREV, independent of the microbiome question. What is not yet established is that testing or deliberately manipulating your gut microbiome, through probiotics, specific supplements, or commercial microbiome tests, adds any proven cardiovascular benefit on top of the diet itself. The review states plainly that the gut microbiome is "a plausible mediator and modifier" of the Mediterranean diet's cardiovascular protection, not a validated clinical target you can currently act on directly. Anyone with existing heart disease, diabetes, or metabolic syndrome who wants to change their diet significantly should still do so in conversation with a doctor or dietitian, particularly if they are on medications like statins or blood thinners.

The 10 to 20 Percent Mediation Estimate Remains Unreplicated

The review is candid about how thin some of the mechanistic evidence still is. The 10 to 20% mediation figure comes from a single trial's exploratory statistical analysis (the DIRECT-PLUS study) and has not yet been independently replicated in another cohort. Several of the trials summarized, including a crossover study by Galié and colleagues, found no significant change in overall gut microbial diversity despite real improvements in blood metabolites, meaning the microbiome's role may be more about which specific bacterial functions shift than a simple more-diversity-is-better story. Most of the underlying evidence also relies on surrogate markers, cholesterol, blood pressure, insulin resistance, and inflammatory markers, rather than tracking who actually goes on to have a heart attack or stroke, and global diversity metrics have been inconsistent across studies. The review authors themselves describe the effects as heterogeneous across trials, and note the gut microbiome remains a research target, not yet a clinical one.

Researchers Call for Longitudinal Multiomic Studies and Pragmatic Trials

The review's authors argue the field's next step is longitudinal studies that track the same people's microbiomes repeatedly over time using multiomic approaches (combining genomic, metabolomic, and other molecular data), with standardized analysis methods so results can be compared across studies and externally validated as biomarkers. They also call for pragmatic trials, real-world-style studies testing whether giving people microbiome-informed Mediterranean diet counseling (tailoring dietary advice based on someone's existing gut bacteria) actually improves diet adherence and cardiovascular outcomes, not just biomarkers, compared with standard dietary advice. No timeline is given in the review for when such trials might report results.

Common Questions

Does eating a Mediterranean diet change your gut bacteria? Yes. Multiple randomized trials cited in the review found that following a Mediterranean diet for as little as 8 weeks increased bacteria that ferment fiber into short-chain fatty acids, including Faecalibacterium prausnitzii and Akkermansia muciniphila, while reducing some bacteria linked to inflammation.

Can a gut microbiome test tell me if the Mediterranean diet will help my heart? No. The review states the gut microbiome is not yet a validated clinical target, meaning there is currently no proven way to use a microbiome test to predict or guide your personal cardiovascular response to the diet.

Is the Mediterranean diet proven to prevent heart attacks and strokes? Yes, independent of the microbiome question. Trials including PREDIMED (primary prevention) and CORDIOPREV (secondary prevention, with a 27% event reduction in patients with existing heart disease over 7 years) have shown fewer cardiovascular events on a Mediterranean diet compared with a low-fat diet.

What foods define a Mediterranean diet in these studies? The trials generally used diets built around legumes, fruits, vegetables, and whole grains, extra-virgin olive oil, nuts, and fish, with reduced red and processed meat, sometimes supplemented specifically with olive oil or walnuts.

References

1. Adrián Hernández-Cacho, Jiaqi Ni, Jesús F. García-Gavilán, et al. (2026). The Role of the Gut Microbiome in the Relationship Between the Mediterranean Diet and Cardiovascular Disease Risk. Current Atherosclerosis Reports. https://doi.org/10.1007/s11883-026-01463-7
2. Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. NIH. https://pubmed.ncbi.nlm.nih.gov/35525255/
3. Ramón Estruch, Emilio Ros, Jordi Salas-Salvadó, et al. (2018). Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1800389